ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate adv...
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...
Frédéric, a biologist by training (ENS, MBA from the College of Engineers), is a recognized leader, with more than 25 years of experience in ...
The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respiratory tract pathogens are notewor...
According to Axion CEO Kevin Gould, “Bringing all of our instruments under the Axion BioSystems umbrella helps ensure all of our customers receive th...
Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for ...
Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specifici...
EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm fo...
Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School Completes Technology Tr...
Hataali – the award winning, leader in digital data solution platforms for advanced therapies – announces a strategic partnership with Reef Gro...
Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dom...
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a ...
The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene el...
© 2026 Biopharma Boardroom. All Rights Reserved.
